ライフサイエンスコーパス: basiliximab

1 ong patients receiving ATG (42% vs. 11% with basiliximab).

2 o weeks later, she received a second dose of basiliximab.

3 iated by immunoglobulin (Ig) E antibodies to basiliximab.

4 imus (0.2mg/kg/day delayed until Day 5) plus basiliximab.

5 al rates, and the safety and tolerability of basiliximab.

6 urrence of dnDSA and ABMR when compared with basiliximab.

7 ents having received either Thymoglobulin or basiliximab.

8 of mycophenolate mofetil and induction with basiliximab.

9 -2 receptor (anti-CD25) monoclonal antibody, basiliximab.

10 ction immunosuppression was with intravenous basiliximab (10 mg on postoperative days 0 and 4).

11 atients was lower with alemtuzumab than with basiliximab (10% vs. 22%, P=0.003), but among high-risk

12 Two hundred twenty-nine patients (102 basiliximab, 127 controls) were analyzed, mean age 54 ye

13 uction, transitional era, 1994 to 2002, when basiliximab (1998), daclizumab (1998), and rabbit antith

14 y ACR was more frequent in SPKT induced with basiliximab (2-year 12.8% vs. 3.1%, P=0.04), but the inc

15 n = 17) or nondepleting, anti-CD25 antibody (basiliximab, 2 x 40 mg, n = 25) induction therapy, in co

16 Patients received either basiliximab (20 mg on day 0 and day 4 posttransplantatio

17 lantation (day 0) and on days 1 through 4 or basiliximab (20 mg, 137 patients) on days 0 and 4.

18 The dose of basiliximab-20-mg infusions on day 0 and day 4-was selec

19 tal of 260 kidney-only recipients were given basiliximab (232) or thymoglobulin (28) induction, and s

20 was not significantly different between the basiliximab (29%) and placebo (43%) groups (P=0.16).

21 ti-IL-2 receptor mAb) for induction therapy (basiliximab: 5 mg intravenously on days 0 and 4) plus lo

22 occurred significantly less frequently with basiliximab (54%) than placebo (73%) (P=0.046).

23 ast 1 dose of study medication (70 patients, basiliximab; 65 patients, ATG).

24 umab (one dose of 30 mg, in 164 patients) or basiliximab (a total of 40 mg over 4 days, in 171 patien

25 se III study was performed to assess whether basiliximab, a chimeric anti-interleukin-2 receptor mono

26 Basiliximab, a chimeric monoclonal antibody directed aga

27 ab, and 26% of those given the 20-mg dose of basiliximab achieved clinical remission (P = 1.00 vs pla

28 l-directed therapies including halofuginone, basiliximab, alemtuzumab, abatacept and rapamycin have b

29 survival was similar in both groups (2-year basiliximab/alemtuzumab 94.7%/91.2%), but death-censored

30 nt with daclizumab (alone or with steroids), basiliximab alone, or steroids alone.

31 antibody TS-1/22 in combination with either basiliximab (an IL-2Ralpha-specific mAb) and sirolimus (

32 rabbit antithymocyte polyclonal antibody or basiliximab, an interleukin-2 receptor monoclonal antibo

33 creatinine at 12 months was 141 mumol/L with basiliximab and 164 mumol/L with placebo (not significan

34 t and patient survivals were 88% and 98% for basiliximab and 88% and 96% for placebo (not significant

35 ection was 19% and 20%, respectively, in the basiliximab and ATG groups.

36 hic characteristics were similar between the basiliximab and ATG-treatment groups.

37 ion (6% vs. 6%; P=0.90) were similar between basiliximab and control groups, respectively.

38 val and renal function were compared between basiliximab and control groups.

39 plus standard-dose Tac; both groups received basiliximab and corticosteroids.

40 Basiliximab and cyclosporine had little effect on apopto

41 Basiliximab and daclizumab are potent and relatively saf

42 enal graft failure than nondepleting agents (basiliximab and daclizumab).

43 nd mycophenolate mofetil plus induction with basiliximab and LFA-1 blockade.

44 75mg/kg/day) immediately posttransplant plus basiliximab and MMF (without maintenance corticosteroids

45 re no immediate side effects associated with basiliximab and no evidence of cytomegalovirus infection

46 no significant differences in safety between basiliximab and placebo in both diabetic and nondiabetic

47 Adverse events were similar in the basiliximab and placebo treatment groups.

48 rATG recipients, but did not differ between basiliximab and rATG recipients.

49 , 163 days) compared to recipients receiving basiliximab and sirolimus alone (graft survival time 8,

50 CTLA4Ig plus 3A8, basiliximab and sirolimus was well tolerated and induced

51 llogeneic islet transplantation and received basiliximab and sirolimus with or without 2C10.

52 ays compared to 8 days in controls receiving basiliximab and sirolimus; p = 0.022).

53 lacebo, 29% of those given the 40-mg dose of basiliximab, and 26% of those given the 20-mg dose of ba

54 .2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids given only perioperativ

55 = 5) were treated with alefacept in place of basiliximab, and more intense LFA-1 blockade.

56 A prolonged-release tacrolimus, basiliximab, and mycophenolate mofetil immunosuppressive

57 2), patients received tacrolimus, steroids, basiliximab, and sirolimus.

58 -interleukin-2 receptor monoclonal antibody, basiliximab, and the rabbit antihuman thymocyte preparat

59 rofile of adverse events was similar between basiliximab- and ATG-treated patients, adverse events co

60 2) receptor (CD25) monoclonal antibody (mAb) basiliximab (anti-IL-2 receptor mAb) for induction thera

61 lls was associated with the presence of anti-basiliximab antibodies (odds ratio, 21; 95% confidence i

62 er in the alemtuzumab group (n=6 vs. n=14 in basiliximab arm) just reaching statistical significance

63 elease tacrolimus (0.15-0.175mg/kg/day) plus basiliximab; Arm 3: prolonged-release tacrolimus (0.2mg/

64 We investigated the efficacy and safety of basiliximab as a corticosteroid-sensitizing agent in pat

65 At 12 months, basiliximab as compared with placebo reduced the proport

66 e with the substitution of thymoglobulin for basiliximab as induction therapy for recipients at incre

67 recipients having received Thymoglobulin or basiliximab as induction therapy.

68 0) and the anti-interleukin (IL)-2R antibody basiliximab, as part of a phase 2 study.

69 ring rabbit antithymocyte globulin (TMG) and basiliximab (BAS) induction in renal transplant recipien

70 antithymocyte globulin (r-ATG)/EVR (N = 85); basiliximab (BAS)/EVR (N = 102); BAS/MPS (N = 101).

71 matched controls induced with alemtuzumab or basiliximab (Bas)/low-dose rabbit anti-thymocyte globuli

72 It is not clear whether the efficacy of basiliximab (BSX) is different from that of Thymoglobuli

73 ACR is better prevented by alemtuzumab than basiliximab, but no relevant difference is found in prev

74 Basiliximab combined with early initiation of cyclospori

75 All patients received basiliximab +/- corticosteroids.

76 CRT recipients received basiliximab, corticosteroids, mycophenolate mofetil (MMF

77 Immunosuppression comprised of basiliximab, cyclosporine, sirolimus, and steroid minimi

78 present, with most patients receiving rATG, basiliximab, daclizumab, or alemtuzumab (2003).

79 All patients received two 20-mg doses of basiliximab (days 0 and 4 after transplantation) followe

80 Sirolimus also delays the repopulation of basiliximab-depleted CD25 T cells compared with cyclospo

81 Basiliximab does not increase the effect of corticostero

82 In addition, basiliximab does not increase the incidence of adverse e

83 Our study shows that induction therapy with basiliximab enabled SDZ RAD blood levels to be significa

84 High immune responders treated with basiliximab expressed a higher mean serum creatinine lev

85 ted a novel immunosuppressive combination of basiliximab for induction and of RAD and FTY720 for main

86 Immunosuppression consisted of basiliximab for induction therapy and tacrolimus, mycoph

87 A strategy combining sirolimus with basiliximab for low-immunologic risk recipients and thym

88 ntly lower in the alemtuzumab group than the basiliximab group (0.12 +/- 0.29 vs 0.74 +/- 0.67; P < 0

89 er rejection was significantly higher in the basiliximab group (P < 0.0001).

90 hymoglobulin group and 28 (73%) of 38 in the basiliximab group (P=0.77).

91 Five (2.9%) deaths in the basiliximab group and seven (4.0%) in the placebo group

92 The antithymocyte globulin group and the basiliximab group had similar incidences of graft loss (

93 ymocyte globulin group, as compared with the basiliximab group, had lower incidences of acute rejecti

94 In the basiliximab group, the predominant cause of kidney loss

95 odialysis at LT (29% vs. 6%; P<0.001) in the basiliximab group.

96 for alemtuzumab group and 53+/-21 mL/min for basiliximab group; P=0.42).

97 Six subjects who received basiliximab had serious adverse events (6.1%) compared w

98 Basiliximab improved the maximal proliferation count in

99 Basiliximab in combination with a tacrolimus-based immun

100 tudy, we assessed the efficacy and safety of basiliximab in combination with a tacrolimus-based regim

101 short courses of antithymocyte globulin and basiliximab in patients at high risk for acute rejection

102 rapy changed during the study timeframe from basiliximab in the NG group to alemtuzumab in the no NG

103 In subjects given basiliximab, incomplete saturation of CD25 (<50%) on per

104 dermal administration of a 1:100 dilution of basiliximab induced a 10 x 10-mm flare.

105 We compared LT outcomes using basiliximab induction and delayed CNI initiation to cont

106 Immunosuppression was basiliximab induction and maintenance was a calcineurin

107 irolimus (n=31) or cyclosporine (n=30) after basiliximab induction and mycophenolate mofetil (MMF) wi

108 Calcineurin inhibitor drug avoidance with basiliximab induction and sirolimus provides comparable

109 Thymoglobulin and basiliximab induction and tacrolimus-based immunosuppres

110 no major differences detected compared with basiliximab induction and tacrolimus/MMF maintenance at

111 een adult patients were randomized to either basiliximab induction followed by tacrolimus and MMF mai

112 ve steroid-free CsA therapy, suggesting that basiliximab induction may be useful as a strategy in oth

113 Basiliximab induction resulted in 30-day and 1-year pati

114 in the presence of everolimus, steroids and basiliximab induction results in good efficacy in de nov

115 Basiliximab induction therapy did not influence CD4 and

116 Basiliximab induction was associated with improved graft

117 nduction with tacrolimus monotherapy against basiliximab induction with tacrolimus and mycophenolate

118 (no induction) compared with CRT recipients (basiliximab induction), despite similar chronic immunosu

119 islets using the CD40-specific antibody 3A8, basiliximab induction, and sirolimus with or without CTL

120 All subjects received basiliximab induction, mycophenolate mofetil, and cortic

121 All patients received basiliximab induction, mycophenolic acid and corticoster

122 /mL), acute rejection (time-dependent), age, basiliximab induction, sex, donor age, human leukocyte a

123 Immunosuppression included basiliximab induction, tacrolimus, and prednisone (+/- s

124 levels of CsA-ME because of the addition of basiliximab induction.

125 immunosuppressive treatment with or without basiliximab induction.

126 ceived antithymocyte globulin and 2 received basiliximab induction.

127 therapy versus those treated with anti-CD25 (Basiliximab) induction therapy and maintenance immunosup

128 BACKGROUND & AIMS: Basiliximab is a chimeric monoclonal antibody that binds

129 regimen and comparable effectiveness to ATG, basiliximab is an attractive choice for the prevention o

130 Basiliximab is associated with a significant reduction i

131 After basiliximab levels fell below the minimum therapeutic le

132 ients received prolonged-release tacrolimus, basiliximab, mycophenolate mofetil and 1 bolus of intrao

133 Basiliximab, mycophenolate mofetil, and corticosteroids

134 All patients received induction therapy with basiliximab, mycophenolate mofetil, and corticosteroids.

135 ed to belatacept or tacrolimus combined with basiliximab, mycophenolate mofetil, and prednisolone.

136 Sixty patients (Thymoglobulin n=22 and basiliximab n=38) were included.

137 nal allograft recipients who received either basiliximab (n=115) or thymoglobulin (n=30) in combinati

138 sion: antithymocyte globulin (ATG) (n=85) or basiliximab (n=29) and were followed up for 36 months.

139 th alemtuzumab (n=97) and those induced with basiliximab (n=39).

140 calcineurin inhibitor (CNI) (cyclosporine A)/basiliximab (n=4) or CNI (tacrolimus)-based immunosuppre

141 plantation patients treated with tofacitinib/basiliximab (n=5), calcineurin inhibitor (CNI) (cyclospo

142 lant recipients were randomized and received basiliximab (n=52) or placebo (n=56) to assess whether b

143 atient received induction therapy with 20 mg basiliximab on days 0 and 4, and maintenance therapy wit

144 Following either basiliximab or alemtuzumab induction patients with lower

145 an either low immune responders treated with basiliximab or high immune responders treated with thymo

146 s superiority of thymoglobulin compared with basiliximab or no antibody induction therapy for 6-month

147 Patients receiving basiliximab or no induction therapy served as controls.

148 ose that patients who develop anaphylaxis to basiliximab or other chimeric antibodies may be candidat

149 were given 20 mg (n = 46) or 40 mg (n = 52) basiliximab or placebo (n = 51) at weeks 0, 2, and 4.

150 ed, equally sized groups treated with either basiliximab or placebo.

151 emtuzumab or conventional induction therapy (basiliximab or rabbit antithymocyte globulin).

152 in 2001 to 2005 managed with thymoglobulin, basiliximab, or no antibody induction and discharge main

153 Compared with placebo, a higher fraction of basiliximab patients produced urine in the operating roo

154 ndicates that, compared with alemtuzumab and basiliximab, rATG associates with lower risk of adverse

155 tithymocyte globulin (rATG) (5330 pairs) and basiliximab-rATG (9378 pairs) recipients.

156 Compared with rATG recipients, basiliximab recipients had higher risk of death (HR, 1.0

157 ually divided into the two treatment groups, basiliximab reduced the proportion of patients who exper

158 of antithymocyte globulin, as compared with basiliximab, reduced the incidence and severity of acute

159 b (n=52) or placebo (n=56) to assess whether basiliximab reduces the need for addition of steroids or

160 sk than CRT recipients who were administered basiliximab (relative risk: 3.6, P<0.002).

161 se findings demonstrate that the addition of basiliximab significantly reduces the need to modify the

162 Basiliximab (Simulect), a chimeric anti-interleukin-2 re

163 Basiliximab (Simulect), a high-affinity chimeric, monocl

164 interleukin-2 receptor antibodies (IL-2RAs): basiliximab (Simulect; Novartis, Basel, Switzerland) and

165 tokine-induced JAK/STAT5 activation, whereas basiliximab suppresses IL-2-stimulated activation only.

166 l intent-to-treat population (143 tacrolimus/basiliximab [Tac/Bas], 139 tacrolimus/mycophenolate mofe

167 rt of 569 patients administered standardized basiliximab-tacrolimus-mycophenolate-corticosteroid immu

168 Prophylactic basiliximab therapy is well tolerated, has an adverse ev

169 Patients who were randomized to basiliximab therapy received a 20 mg i.v. bolus dose on

170 Basiliximab therapy showed an excellent safety profile,

171 sponse to IL-2 decreased after both rATG and basiliximab therapy.

172 signed to compare the safety and efficacy of basiliximab to polyclonal anti-T-cell (ATGAM) therapy fo

173 We previously reported that the use of basiliximab together with sirolimus permits a window of

174 Graft losses occurred in 9 (5.2%) basiliximab-treated and 12 (6.9%) placebo-treated patien

175 Basiliximab-treated high immune responders exhibited a h

176 f acute rejection episodes (26%) than either basiliximab-treated low immune responders (10%, P=0.04)

177 During the first 12 months, 94 (54%) basiliximab-treated patients experienced serious adverse

178 During the trial, 33% of basiliximab-treated patients received oral steroids at s

179 t, risk reduction among thymoglobulin versus basiliximab-treated patients was of larger magnitude but

180 By the end of the study, 25% of basiliximab-treated patients were receiving maintenance

181 differences in expression between rATG- and basiliximab-treated patients.

182 Conventional immunosuppressive or basiliximab treatment cannot control the persistence of

183 In contrast, CNI/basiliximab treatment did not affect IL-7-activated or I

184 patients, 7 days after starting tofacitinib/basiliximab treatment, cytokine-induced P-STAT5 was inhi

185 intained in diabetic recipients treated with basiliximab versus placebo (96% vs. 86%; P=0.022).

186 e randomized to receive either daclizumab or basiliximab versus RATG for induction in combination wit

187 ncidence of AMR was similar (2-year 18% with basiliximab vs. 13.8% with alemtuzumab, P=NS).

188 acute rejection episodes by 28%: 61 (35.3%) basiliximab vs. 85 (49.1%) placebo (P=0.009).

189 Basiliximab was generally well tolerated.

190 In multivariable logistic regression, basiliximab was not significantly associated with 30-day

191 py with alemtuzumab or IL-2RA (daclizumab or basiliximab) was used.

192 le endpoint with thymoglobulin compared with basiliximab when steroids were present, with approximate

193 patients received everolimus, steroids, and basiliximab with low or standard tacrolimus exposure.

194 ducted to compare the efficacy and safety of basiliximab with placebo in renal transplant recipients

195 changed our primary induction protocol from basiliximab with standard maintenance immunosuppression

196 ne, rATG with steroids, rATG alone, and then basiliximab with steroids.

197 ore </=2, no subscore >1) for patients given basiliximab with the rate for patients given placebo.

198 e treatment (mycofenolate mofetil, steroids, basiliximab) with delayed introduction of sirolimus in p

199 t a 42-year-old woman who received a dose of basiliximab without adverse reaction before an anticipat